Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangement - PubMed
2 hours ago
- #NUP98 rearrangement
- #acute myeloid leukemia
- #clinical outcomes
- Study analyzes 95 adult AML patients with NUP98 rearrangements, characterized by young median age (50 years), high WBC count, and frequent FLT3-ITD (48%) and WT1 mutations (34%).
- NUP98::NSD1 fusion is most common (54%), associated with younger age, more de novo AML, higher rates of normal karyotype, FLT3-BITD, and WT1 mutations compared to other NUP98 rearrangements.
- Median overall survival for the cohort is 15.2 months; FLT3 inhibitor therapy and hematopoietic stem cell transplant improve outcomes, with FLT3 inhibitors leading to 5-year OS of 53.3%, approaching intermediate-risk patient prognosis.